Lakefront Biotherapeutics NV annual current ratio
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Lakefront Biotherapeutics NV Current Ratio Growth & History (LKFT)
Lakefront Biotherapeutics NV's current ratio was 20.15 for fiscal 2025.
View full Lakefront Biotherapeutics NV company overviewLakefront Biotherapeutics NV annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 20.15 | 10.18 | +102.14% |
| 2024 | 2024-12-31 | 9.97 | 0.95 | +10.52% |
| 2023 | 2023-12-31 | 9.02 | 0.91 | +11.22% |
| 2022 | 2022-12-31 | 8.11 | −0.47 | −5.53% |
| 2021 | 2021-12-31 | 8.58 | 0.13 | +1.55% |
| 2020 | 2020-12-31 | 8.45 | −1.81 | −17.61% |
| 2019 | 2019-12-31 | 10.26 | 4.22 | +69.77% |
| 2018 | 2018-12-31 | 6.04 | −0.93 | −13.37% |
| 2017 | 2017-12-31 | 6.98 | −2.73 | −28.12% |
| 2016 | 2016-12-31 | 9.70 | 4.53 | +87.66% |
| 2015 | 2015-12-31 | 5.17 | — | — |
Lakefront Biotherapeutics NV quarterly current ratio
Q2.18
Q4.18
Q2.19
Q4.19
Q2.20
Q4.20
Q2.21
Q4.21
Q4.22
Q4.23
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 32.84 | 24.76 | +306.49% |
| Q1 2026 | 2026-03-31 | 30.48 | 22.53 | +283.61% |
| Q4 2025 | 2025-12-31 | 20.15 | 10.18 | +102.14% |
| Q3 2025 | 2025-09-30 | 8.63 | — | — |
| Q2 2025 | 2025-06-30 | 8.08 | — | — |
| Q1 2025 | 2025-03-31 | 7.95 | — | — |
| Q4 2024 | 2024-12-31 | 9.97 | 0.95 | +10.52% |
| Q4 2023 | 2023-12-31 | 9.02 | 0.91 | +11.22% |
| Q4 2022 | 2022-12-31 | 8.11 | −0.47 | −5.53% |
| Q4 2021 | 2021-12-31 | 8.58 | 0.13 | +1.55% |
| Q2 2021 | 2021-06-30 | 8.89 | −0.20 | −2.19% |
| Q4 2020 | 2020-12-31 | 8.45 | −1.81 | −17.61% |
| Q2 2020 | 2020-06-30 | 9.09 | 2.68 | +41.92% |
| Q4 2019 | 2019-12-31 | 10.26 | 4.22 | +69.77% |
| Q2 2019 | 2019-06-30 | 6.40 | 1.91 | +42.55% |
| Q4 2018 | 2018-12-31 | 6.04 | — | — |
| Q2 2018 | 2018-06-30 | 4.49 | — | — |
Lakefront Biotherapeutics NV current ratio trends
Over the last five fiscal years, Lakefront Biotherapeutics NV's current ratio increased from 8.45 to 20.15, a change of 11.69. The latest reported quarter, Q2 2026, shows 32.84.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lakefront Biotherapeutics NV source filings ↗